沙库巴曲缬沙坦在难治性高血压患者中的研究进展
Research Progress of Sacubitril/Valsartan in the Treatment of Patients with Resistant Hypertension
摘要: 难治性高血压以盐敏感性增加引起的夜间血压升高为主要特征，是心血管不良事件的主要可控危险因素之一，其治疗目前依旧是一个具有挑战性的临床问题。沙库巴曲缬沙坦(LCZ696)是一种新型的血管紧张素受体脑啡肽酶抑制剂，其在降压及逆转心室重塑中的优势已被证实。此外，相比于白天血压，其对夜间血压改善更为显著。因此，结合先前研究我们考虑LCZ696可能是一种治疗难治性高血压的潜在有效药物，不仅可以用于难治性高血压的二级预防，还可能有效延缓难治性高血压向心衰的进展。现就LCZ696药理作用及其在高血压尤其是难治性高血压中的应用进行综述，以期为难治性高血压的治疗提供新的临床思路。
Abstract: Resistant hypertension (RHTN), characterized by increased nocturnal blood pressure (BP) induced by elevated salt sensitivity, is a significant controllable risk factor for adverse cardiovascular events. The treatment of RHTN is still a challenging clinical problem. Sacubitril/valsartan (LCZ696), an an-giotensin receptor neprilysin inhibitor, has been demonstrated to effectively reduce BP and reverse ventricular remodeling. Besides, the decrease in nocturnal BP caused by LCZ696 was more signifi-cant than that of daytime BP. Thus, based on previous research, we propose that LCZ696 could be a potentially effective drug for RHTN, which may not only be used as the secondary prevention of RHTN, but also slow the progression from RHTN to heart failure. This review describes the pharma-cological effects of LCZ696 and gives an overview of its application in the treatment of hypertension especially in RHTN in order to provide a new clinical idea for the treatment of RHTN.
文章引用：宋丽雪, 王娟. 沙库巴曲缬沙坦在难治性高血压患者中的研究进展[J]. 临床医学进展, 2024, 14(1): 1815-1820. https://doi.org/10.12677/ACM.2024.141258

参考文献

[1] Daugherty, S.L., Powers, J.D., Magid, D.J., et al. (2012) Incidence and Prognosis of Resistant Hypertension in Hyper-tensive Patients. Circulation, 125, 1635-1642. [Google Scholar] [CrossRef] 
[2] Carey, R.M., Calhoun, D.A., Bakris, G.L., et al. (2018) Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement from the American Heart Association. Hypertension (Dallas, Tex: 1979), 72, E53-E90. [Google Scholar] [CrossRef] 
[3] Acelajado, M.C., Hughes, Z.H., Oparil, S., et al. (2019) Treatment of Resistant and Refractory Hypertension. Circulation Research, 124, 1061-1070. [Google Scholar] [CrossRef] 
[4] Bangalore, S., Fayyad, R., Laskey, R., et al. (2014) Prevalence, Predictors, and Outcomes in Treatment-Resistant Hypertension in Patients with Coronary Disease. The American Journal of Medicine, 127, 71-81.e1. [Google Scholar] [CrossRef] [PubMed]
[5] Groenland, E.H., Bots, M.L., Asselbergs, F.W., et al. (2021) Apparent Treatment Resistant Hypertension and the Risk of Recurrent Cardiovascular Events and Mortality in Patients with Established Vascular Disease. International Journal of Cardiology, 334, 135-141. [Google Scholar] [CrossRef] [PubMed]
[6] 韩魁, 张晨. 难治性高血压诊治的研究进展[J]. 实用心脑肺血管病杂志, 2019, 27(S2): 233-236.
[7] 邹金兵, 韩津津, 韩丽华. 难治性高血压的定义演变与最新研究进展[J]. 中国医学创新, 2021, 18(8): 175-179.
[8] Grassi, G., Mark, A. and Esler, M. (2015) The Sympathetic Nervous Sys-tem Alterations in Human Hypertension. Circulation Research, 116, 976-990. [Google Scholar] [CrossRef] 
[9] 孙宁玲, 霍勇, 王继光, 等. 难治性高血压诊断治疗中国专家共识[J]. 中国医学前沿杂志(电子版), 2013, 5(6): 10-17.
[10] Zhang, J., Liang, J., Zhang, X., et al. (2021) Non-Invasive Systemic Hemodynamic Index in Vascular Risk Stratification Tailored for Hypertensives. Frontiers in Cardiovascular Medicine, 8, Article ID: 744349. [Google Scholar] [CrossRef] [PubMed]
[11] Pimenta, E., Gaddam, K.K., Oparil, S., et al. (2009) Effects of Die-tary Sodium Reduction on Blood Pressure in Subjects with Resistant Hypertension: Results from a Randomized Trial. Hypertension (Dallas, Tex: 1979), 54, 475-481. [Google Scholar] [CrossRef] 
[12] Bloch, M.J. and Basile, J.N. (2010) Combina-tion Angiotensin Receptor Blocker-Neutral Endopeptidase Inhibitor Provides Additive Blood Pressure Reduction over Angiotensin Receptor Blocker Alone. The Journal of Clinical Hypertension (Greenwich), 12, 809-812. [Google Scholar] [CrossRef] [PubMed]
[13] Abdin, A., Schulz, M., Riemer, U., et al. (2022) Sacubi-tril/Valsartan in Heart Failure: Efficacy and Safety in and Outside Clinical Trials. ESC Heart Failure, 9, 3737-3750. [Google Scholar] [CrossRef] [PubMed]
[14] Vaduganathan, M., Mentz, R.J., Claggett, B.L., et al. (2023) Sacubi-tril/Valsartan in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Pre-Specified Participant-Level Pooled Analysis of PARAGLIDE-HF and PARAGON-HF. European Heart Journal, 44, 2982-2993. [Google Scholar] [CrossRef] [PubMed]
[15] Gu, J., Noe, A., Chandra, P., et al. (2010) Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi). Journal of Clinical Pharmacology, 50, 401-414. [Google Scholar] [CrossRef] [PubMed]
[16] Mangiafico, S., Costello-Boerrigter, L.C., Andersen, I.A., et al. (2013) Neutral Endopeptidase Inhibition and the Natriuretic Peptide System: An Evolving Strategy in Cardiovascular Therapeutics. European Heart Journal, 34, 886-893. [Google Scholar] [CrossRef] [PubMed]
[17] Mitchell, G.F., Izzo, J.L., Lacourci, R.E., et al. (2002) Omapatrilat Reduces Pulse Pressure and Proximal Aortic Stiffness in Patients with Systolic Hypertension: Results of the Conduit Hemodynamics of Omapatrilat International Research Study. Circulation, 105, 2955-2961. [Google Scholar] [CrossRef] 
[18] Kostis, J.B., Packer, M., Black, H.R., et al. (2004) Omapatrilat and Enalapril in Patients with Hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) Trial. American Journal of Hypertension, 17, 103-111. [Google Scholar] [CrossRef] [PubMed]
[19] Ruilope, L.M., Dukat, A.B., et al. (2010) Blood-Pressure Re-duction with LCZ696, a Novel Dual-Acting Inhibitor of the Angiotensin II Receptor and Neprilysin: A Randomised, Double-Blind, Placebo-Controlled, Active Comparator Study. The Lancet (London, England), 375, 1255-1266. [Google Scholar] [CrossRef] 
[20] Kario, K., Sun, N., Chiang, F.T., et al. (2014) Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients with Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study. Hypertension (Dallas, Tex: 1979), 63, 698-705. [Google Scholar] [CrossRef] 
[21] Mcmurray, J.J., Packer, M., Desai, A.S., et al. (2014) Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. The New England Journal of Medicine, 371, 993-1004. [Google Scholar] [CrossRef] 
[22] Kario, K. (2013) Proposal of a New Strategy for Ambu-latory Blood Pressure Profile-Based Management of Resistant Hypertension in the Era of Renal Denervation. Hyperten-sion Research: Official Journal of the Japanese Society of Hypertension, 36, 478-484. [Google Scholar] [CrossRef] [PubMed]
[23] Kario, K., Tamaki, Y., Okino, N., et al. (2016) LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients with Severe Hypertension. Journal of Clinical Hypertension (Greenwich, Conn), 18, 308-314. [Google Scholar] [CrossRef] [PubMed]
[24] Williams, B., Cockcroft, J.R., Kario, K., et al. (2017) Effects of Sacubitril/Valsartan versus Olmesartan on Central Hemodynamics in the Elderly with Systolic Hypertension: The PARAMETER Study. Hypertension (Dallas, Tex: 1979), 69, 411-420. [Google Scholar] [CrossRef] 
[25] Supasyndh, O., Sun, N., Kario, K., et al. (2017) Long-Term (52-Week) Safety and Efficacy of Sacubitril/Valsartan in Asian Patients with Hypertension. Hypertension Research: Official Journal of the Japanese Society of Hypertension, 40, 472-476. [Google Scholar] [CrossRef] [PubMed]
[26] Wang, J.G., Yukisada, K., Sibulo, A., et al. (2017) Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Add-On to Amlodipine in Asian Patients with Systolic Hypertension Uncontrolled with Amlodipine Monotherapy. Journal of Hypertension, 35, 877-885. [Google Scholar] [CrossRef] 
[27] Almarjan, A.I., Almarjan, S.A. and Masoud, A.T. (2023) Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis. High Blood Pressure & Cardiovascular Prevention: The Official Journal of the Italian Soci-ety of Hypertension, 30, 207-218. [Google Scholar] [CrossRef] [PubMed]
[28] Packer, M., Mcmurray, J.J., Desai, A.S., et al. (2015) Angioten-sin Receptor Neprilysin Inhibition Compared with Enalapril on the Risk of Clinical Progression in Surviving Patients with Heart Failure. Circulation, 131, 54-61. [Google Scholar] [CrossRef] 
[29] Jackson, A.M., Jhund, P.S., Anand, I.S., et al. (2021) Sacubitril-Valsartan as a Treatment for Apparent Resistant Hypertension in Patients with Heart Failure and Pre-served Ejection Fraction. European Heart Journal, 42, 3741-3752. [Google Scholar] [CrossRef] [PubMed]
[30] Li, W., Gong, M., Yu, Q., et al. (2022) Efficacy of Angiotensin Re-ceptor Neprilysin Inhibitor in Asian Patients with Refractory Hypertension. Journal of Clinical Hypertension (Greenwich, Conn), 24, 449-456. [Google Scholar] [CrossRef] [PubMed]
[31] Kusaka, H., Sueta, D., Koibuchi, N., et al. (2015) LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More than Valsartan Alone. American Journal of Hypertension, 28, 1409-1417. [Google Scholar] [CrossRef] [PubMed]
[32] Li, X., Braza, J., Mende, U., et al. (2021) Cardioprotective Effects of Early Intervention with Sacubitril/Valsartan on Pres-sure Overloaded Rat Hearts. Scientific Reports, 11, Article No. 16542. [Google Scholar] [CrossRef] [PubMed]
[33] Shi, Y.J., Yang, C.G., Qiao, W.B., et al. (2023) Sacubi-tril/Valsartan Attenuates Myocardial Inflammation, Hypertrophy, and Fibrosis in Rats with Heart Failure with Preserved Ejection Fraction. European Journal of Pharmacology, 961, Article ID: 176170. [Google Scholar] [CrossRef] [PubMed]
[34] Chen, J., Pei, Y., Wang, Q., et al. (2023) Effect of Sacubi-tril/Valsartan or Valsartan on Ventricular Remodeling and Myocardial Fibrosis in Perimenopausal Women with Hyper-tension. Journal of Hypertension, 41, 1077-1083. [Google Scholar] [CrossRef] 
[35] Lyu, T.J., Liu, Y., Zhang, H., et al. (2022) Clinical Observa-tion of Sacubitril Valsartan Sodium in the Treatment of Resistant Hypertension: A Randomized Clinical Trial. Frontiers in Cardiovascular Medicine, 9, Article ID: 1099043. [Google Scholar] [CrossRef] [PubMed]
[36] Wang, B., Wang, G.H., Ding, X.X., et al. (2022) Effects of Sacu-bitril/Valsartan on Resistant Hypertension and Myocardial Work in Hemodialysis Patients. Journal of Clinical Hyperten-sion (Greenwich, Conn), 24, 300-308. [Google Scholar] [CrossRef] [PubMed]

为你推荐